Join our mailing list!
(Your shopping cart is empty)
Diane Publishing Books
Drug Safety: FDA Needs to Further Address Shortcomings in Its Postmarket Decisionmaking Process: Testimony Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, U.S. House of Representatives
Marcia Crosse (au)
Statement of Marcia Crosse, Dir., Health Care, GAO. In 2004, several high-profile drug safety cases raised concerns about the Food & Drug Admin.’s (FDA) ability to manage postmarket drug safety issues. In some cases there were disagreements within FDA about how to address these issues. GAO was asked to testify on the effectiveness of FDA’s postmarket decision-making process. This testimony is based on the GAO report, “Drug Safety: Improvement Needed in FDA’s Postmarket Decisionmaking & Oversight Process,” which focused on the complex interaction between the two offices within FDA that are involved in postmarket drug safety activities: the Office of New Drugs (OND), & the Office of Drug Safety (ODS). OND’s primary responsibility is to review new drug applications, but it is also involved in monitoring the safety of marketed drugs. ODS is focused primarily on postmarket drug safety issues. ODS is now called the Office of Surveillance & Epidemiology.
Language Imperative: How Learning Languages Can Enrich Your Life & Expand Your Mind
We the People: Voices & Images of the New Nation
Small Sects in America (rev. ed.)
Censored Hollywood: Sex, Sin, & Violence on Screen
Peter Pan: The Original Tale of Neverland
Sale Price: $13.00
Share your knowledge of this product with other customers...
Be the first to write a review
Diane Publishing Co
PO Box 617
Darby, PA 19023-0617
Become an Affiliate
Send Us Feedback
Copyright ï¿½ 2004 Diane Publishing Company. All Rights Reserved.